It has recently been suggested that CCND1 amplification may be associated with poor response to antiestrogen therapy and that ribociclib and abemaciclib may contribute to increased response rates when combined with endocrine therapy in hormone-responsive advanced breast cancer [49]. This evidence concerns the gene CCND1 and breast carcinoma.